Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through ...

Streamlined access to Guardant Shield ™ will help millions of people residing in senior living facilities to stay up to date on colorectal cancer screening LabFlorida/SunDX will provide patients in ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...

Strategic partnership will expand Shield to PathGroup’s 15,000+ primary care and OBGYN physicians PathGroup’s extensive network of phlebotomists and Patient Service Centers enables easier access to ...

Health officials introduce blood test as a more pleasant option to encourage greater participation in screening and boost early detection of colorectal cancer PALO ALTO, Calif.--(BUSINESS ...

Guardant Health delivered a strong start to 2026, outperforming Wall Street’s revenue expectations in Q1 as robust demand ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Partnership will Make Guardant Health Cancer Tests Available to Over 250 Million Patients with a Record in Epic Integration Will Simplify the Process for Clinicians to Order Tests and Access Results ...

Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Physicians nationwide now have the ability to ...

Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay Shield is the first and only blood test approved by the FDA as a ...